Tag Archives: Metformin

Possible Case: Januvia Efectos Secundarios – Januvia Cáncer, Januvia Pancreatitis, Januvia Demand

Home Page Español Januvia

Januvia es un medicamento recetado para tratar a adultos con diabetes tipo 2. En 25 de septiembre de 2009, la FDA emitió una revisión a la etiqueta de advertencia de la droga Januvia o Janumet–un medicamento de combinación compuesto por Januvia y metformina–con respecto a

Read More 0 Comments

UPDATE 1-Ambac says has final deal with bankrupt Detroit over bonds

Fri Jul 25, 2014 11:11am EDT

(Adds details and background of settlement)
July 25 (Reuters) – Ambac Assurance Corp said on
Friday its final settlement in Detroit’s bankruptcy case over
the treatment of limited-tax general obligation bonds that it
insured for the city would result in a 34 percent

Litigator of the Week: Michael Carvin of Jones Day

Two contradictory appellate court rulings this week framed the next battle over Obamacare. Carvin was at the center of both of them.

]]]]]]]]]]>]]]]]]]]>]]]]]]>]]]]>]]>

Already Registered? Sign In now
5 free articles* every 30 days, from other ALM publications
Exclusive discounts on ALM events and products
Litigation Daily digital newsletter,

Time for the Bank of England to show a steady hand

By Helene Durand

Fri Jul 25, 2014 11:58am EDT

LONDON, July 25 (IFR) – The Bank of England’s latest
curveball on the leverage ratio muddles the waters further in
what is already a fiendishly complicated UK bank capital
framework.
Just when UK banks thought it was safe to make

Settlement: Ameriprise Agrees Preliminary Settlement in Securities America Investor Class Action

April 13 2011New York, NY: A preliminary settlement has been reached by Ameriprise Financial and its brokerage unit, Securities America Inc, and clients who allege in they lost roughly $400 million on fraudulent private placements. The preliminary agreement would see Securities America pay $80 million, further to a separate

Possible Lawsuit: Temporary Cognitive Impairment Prompts FDA Labeling Change for Lunesta

May 16 2014Washington, DC: A new warning that the insomnia drug Lunesta (eszopiclone) can cause next-day impairment of driving and other activities that require alertness has been issued by The US Food and Drug Administration (FDA). A study of Lunesta found that the previously recommended dose of 3 mg